H.Res. 903

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 903 Introduced in House (IH)]

<DOC>

119th CONGRESS
1st Session
H. RES. 903

Expressing support for the designation of November as ``Complex 
Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome 
Awareness Month''.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

November 20, 2025

Mr. Tonko (for himself and Mrs. Miller-Meeks) submitted the following 
resolution; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

RESOLUTION

Expressing support for the designation of November as ``Complex 
Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome 
Awareness Month''.

Whereas Complex Regional Pain Syndrome, also known as Reflex Sympathetic 
Dystrophy Syndrome, is a rare, neuro-inflammatory syndrome characterized 
by intense chronic pain, swelling, vascular changes, and functional 
impairment of the limbs that may result from simple trauma, injury, 
infection, or surgery that can lead to disability;
Whereas Complex Regional Pain Syndrome can become debilitating unless diagnosed 
early and treated appropriately;
Whereas although Complex Regional Pain Syndrome was first identified during the 
American Civil War, it remains an obscure and poorly understood 
condition for which there is no single test for diagnosis, and there is 
no cure;
Whereas Complex Regional Pain Syndrome is more common in women than men with a 
ratio of 3.5:1, with peak incidence in middle-aged and older adults, 
especially post menopausal women;
Whereas the incidence of Complex Regional Pain Syndrome is low worldwide, with 
regional rates generally between 5 and 29 per 100,000 individuals, 
higher in women and older adults, and even lower in children;
Whereas individuals with Complex Regional Pain Syndrome, like many other rare 
disorders, experience challenges with obtaining a diagnosis, limited 
treatment options, and difficulty finding and accessing treatment 
centers and physicians with expertise in Complex Regional Pain Syndrome;
Whereas because the disorder affects multiple systems of the body, a patient 
with Complex Regional Pain Syndrome often requires access to care from 
experts across a range of medical specialties;
Whereas, to date, there is no treatment for Complex Regional Pain Syndrome that 
is approved by the Food and Drug Administration (in this resolution 
referred to as the ``FDA'');
Whereas there is a critical need for research and development to advance 
treatments for Complex Regional Pain Syndrome;
Whereas, as a result of the Orphan Drug Act, there have been important advances 
in research on and treatment for rare diseases, including development 
efforts in Complex Regional Pain Syndrome;
Whereas the FDA established the Accelerated Approval Pathway in 1992 and 
Congress codified the pathway in 2012;
Whereas the Accelerated Approval Pathway is an important pathway for rare and 
ultrarare diseases as it allows for ``earlier approval of drugs that 
treat serious conditions, and fill an unmet medical need'';
Whereas Congress and the FDA have affirmed the importance of incorporating the 
patient perspective throughout the drug review process through the FDA's 
Patient-Focused Drug Development program;
Whereas the Reflex Sympathetic Dystrophy Syndrome Association, a nonprofit 
organization founded in 1984 to provide support, education, and hope to 
all affected by the pain and disability of CRPS/RSD, while driving 
research to develop better treatments and a cure for Complex Regional 
Pain Syndrome; and
Whereas ``Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy 
Syndrome Awareness Month'' is expected to be observed in the United 
States for years to come, providing hope and information for patients, 
caregivers, and families around the country: Now, therefore, be it
Resolved, That the House of Representatives--
(1) expresses support for the designation of ``Complex 
Regional Pain Syndrome and Reflex Sympathetic Dystrophy 
Syndrome Awareness Month''; and
(2) recognizes the importance of, with respect to Complex 
Regional Pain Syndrome and Reflex Sympathetic Dystrophy 
Syndrome Awareness Month--
(A) improving awareness;
(B) encouraging accurate and early diagnosis;
(C) advancing research;
(D) developing new treatments, diagnostics, and 
cures; and
(E) identifying regulatory pathways for drug 
development of ultrarare diseases like Complex Regional 
Pain Syndrome and Reflex Sympathetic Dystrophy 
Syndrome.
<all>